[Initial experience with the beta-blocker befunolol in the treatment of open-angle glaucoma in Europe].
The effect and possible side effects of the new beta-blocker Befunolol 0.25% and 0.5% were investigated for the first time in Europe in an open case study lasting 3 months. Good reduction of intraocular pressure was achieved with both concentrations. The statistical evaluation gave no indications of any significant influences on pulse, blood pressure, corneal sensitivity, tear production, pupil diameter, ECG, visual acuity or perimetry. No local side effects were observed and subjective tolerance was good. There was no diminution of the effect on IOP during the 3 months of the study.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C006034:befunolol
Erste Erfahrungen mit dem Beta-Blocker Befunolol bei Glaukomen mit weitem Kammerwinkel in Europa.